CCL2 and neoplasm: These results were complemented by a decrease in mRNA expression of the tumor-promoting factors VEGF (p < 0.0001) and CCL2 (p < 0.0001) to baseline levels in response to CDDO-Me treatment in tumor-educated BMDMs (Figure 2B).